Long-acting injectable Cabenuva is proving to be a versatile and preferred treatment option for adolescents living with HIV, according to data presented at the Conference on Retroviruses and Infectious Diseases (CROI) 2026. ViiV Healthcare reported that over 97% of adolescents in a study preferred the injectable formulation over daily oral medication.
The findings highlight a significant advancement in HIV treatment, particularly for patients who struggle with adherence to daily pill regimens. Cabenuva, a combination of cabotegravir and rilpivirine, offers a long-acting alternative, reducing the frequency of medication administration and potentially improving treatment outcomes. ViiV Healthcare also presented pipeline data indicating potential for twice-yearly dosing of HIV treatments, further streamlining the treatment process.
Beyond adolescent patients, Cabenuva has demonstrated superior efficacy compared to daily oral therapy for individuals facing adherence challenges, as published in the New England Journal of Medicine. This efficacy is particularly relevant as medication adherence remains a critical barrier to successful HIV management. Researchers at the University of Alabama at Birmingham are currently leading a study specifically focused on mitigating these adherence barriers.
The positive data surrounding Cabenuva has been welcomed by the medical community. The Pharma Letter reported the findings as a significant step forward in HIV treatment options. The injectable formulation provides “an important alternative” to daily pills, offering a more convenient and potentially more effective approach for a wider range of patients.
ViiV Healthcare’s ongoing research extends beyond Cabenuva, with investigations into new therapies offering the possibility of even less frequent dosing schedules. The company’s pipeline data suggests a future where HIV treatment could be administered only twice a year, representing a substantial improvement in quality of life for those living with the virus.
